Dr. Geoffrey L. Uy
Claim this profileWashington University School of Medicine
Expert in Acute Myeloid Leukemia
Expert in T-Lymphoblastic Leukemia/Lymphoma
28 reported clinical trials
63 drugs studied
About Geoffrey L. Uy
Education:
- Earned an MD from Washington University School of Medicine.
Experience:
- Over 21 years of clinical experience as an oncologist.
- Specializes in Oncology, with a subspecialty in Hematologic Oncology.
- Affiliated with Barnes-Jewish Hospital and Siteman Cancer Center.
- Recognized for exceptional patient care and high satisfaction ratings.
Area of expertise
1Acute Myeloid Leukemia
Global LeaderFLT3 negative
CD7 positive
FLT3 positive
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderCD7 positive
FLT3 positive
FLT3 negative
Affiliated Hospitals
Clinical Trials Geoffrey L. Uy is currently running
CIML NK Cell Therapy
for Acute Myeloid Leukemia
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).
Recruiting1 award Phase 2
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
More about Geoffrey L. Uy
Clinical Trial Related1 year of experience running clinical trials · Led 28 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Geoffrey L. Uy has experience with
- Cytarabine
- Cyclophosphamide
- Dexamethasone
- Uproleselan
- Cytokine Induced Memory-like NK Cell Adoptive Therapy
- Isatuximab
Breakdown of trials Geoffrey L. Uy has run
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Geoffrey L. Uy specialize in?
Geoffrey L. Uy focuses on Acute Myeloid Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 negative patients, or patients who are CD7 positive.
Is Geoffrey L. Uy currently recruiting for clinical trials?
Yes, Geoffrey L. Uy is currently recruiting for 8 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Geoffrey L. Uy has studied deeply?
Yes, Geoffrey L. Uy has studied treatments such as Cytarabine, Cyclophosphamide, Dexamethasone.
What is the best way to schedule an appointment with Geoffrey L. Uy?
Apply for one of the trials that Geoffrey L. Uy is conducting.
What is the office address of Geoffrey L. Uy?
The office of Geoffrey L. Uy is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.